BRPI1009616B8 - plataforma de imunização para uso em uma estratégia de imunização prime-boost e kit - Google Patents

plataforma de imunização para uso em uma estratégia de imunização prime-boost e kit

Info

Publication number
BRPI1009616B8
BRPI1009616B8 BRPI1009616A BRPI1009616A BRPI1009616B8 BR PI1009616 B8 BRPI1009616 B8 BR PI1009616B8 BR PI1009616 A BRPI1009616 A BR PI1009616A BR PI1009616 A BRPI1009616 A BR PI1009616A BR PI1009616 B8 BRPI1009616 B8 BR PI1009616B8
Authority
BR
Brazil
Prior art keywords
immunization
serotype
vsv
prime
kit
Prior art date
Application number
BRPI1009616A
Other languages
English (en)
Inventor
Kang Chil-Young
Nyoun Kim Gyuong
Original Assignee
Univ Western Ontario
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Western Ontario filed Critical Univ Western Ontario
Publication of BRPI1009616A2 publication Critical patent/BRPI1009616A2/pt
Publication of BRPI1009616B1 publication Critical patent/BRPI1009616B1/pt
Publication of BRPI1009616B8 publication Critical patent/BRPI1009616B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/12011—Betaretrovirus, e.g. mouse mammary tumour virus
    • C12N2740/12041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/12043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

diferentes sorotipos de virus da estomatite vesicular como vetores de expressão para regimes de imunização. plataformas de imunização, regimes de vacinação e medicamentos úteis para induzir uma resposta imune em um mamífero e prevenir ou tratar uma infecção patogênica em um mamífero, em que as ditas plataformas de imunização e medicamentos constituem um vírus recombinante da estomatite vesicular (vsv) de um sorotipo e um rvsv de outro sorotipo e são utilizados em regime de imunização primeboost. em aspectos da invenção um sorotipo vsv é indiana e o outro sorotipo vsv é new jersey.
BRPI1009616A 2009-06-08 2010-06-08 plataforma de imunização para uso em uma estratégia de imunização prime-boost e kit BRPI1009616B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18495909P 2009-06-08 2009-06-08
US61/184,959 2009-06-08
PCT/CA2010/000874 WO2010142030A1 (en) 2009-06-08 2010-06-08 Different serotypes of vesicular stomatitis virus as expression vectors for immunization regimens

Publications (3)

Publication Number Publication Date
BRPI1009616A2 BRPI1009616A2 (pt) 2019-07-16
BRPI1009616B1 BRPI1009616B1 (pt) 2021-05-11
BRPI1009616B8 true BRPI1009616B8 (pt) 2021-05-25

Family

ID=43308343

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1009616A BRPI1009616B8 (pt) 2009-06-08 2010-06-08 plataforma de imunização para uso em uma estratégia de imunização prime-boost e kit

Country Status (9)

Country Link
US (1) US9248178B2 (pt)
EP (1) EP2440244B1 (pt)
JP (1) JP5675789B2 (pt)
KR (1) KR101723900B1 (pt)
AU (1) AU2010258047B2 (pt)
BR (1) BRPI1009616B8 (pt)
CA (1) CA2764903C (pt)
ES (1) ES2533345T3 (pt)
WO (1) WO2010142030A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105555958B (zh) * 2013-06-26 2021-02-05 西安大略大学 水疱性口炎病毒的改性基质蛋白
MX369776B (es) * 2014-03-01 2019-11-21 Univ Texas Vectores recombinantes del virus isfahan.
US20230144060A1 (en) * 2020-04-16 2023-05-11 Sumagen Canada Inc. MERS-CoV VACCINE
US20230149536A1 (en) 2020-04-17 2023-05-18 Vyriad, Inc. Compositions for treating and/or preventing coronavirus infections
IL297237B2 (en) 2020-04-17 2025-08-01 Regeneron Pharma Detection assays for coronavirus neutralizing antibodies
KR20230156918A (ko) * 2021-03-03 2023-11-15 스마젠 캐나다 인크. 재조합 vsv-sars-cov-2 백신
WO2024159071A1 (en) 2023-01-27 2024-08-02 Regeneron Pharmaceuticals, Inc. Modified rhabdovirus glycoproteins and uses thereof
WO2025208054A1 (en) 2024-03-28 2025-10-02 Regeneron Pharmaceuticals, Inc. Recombinant rhabdovirus encoding interleukin-12 (il-12)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1527087B2 (en) * 2002-07-26 2013-07-17 Her Majesty, The Queen in Right of Canada, as Represented by The Minister of Health Recombinant vesicular stomatitis virus vaccines for viral hemorrhagic fevers
NZ542652A (en) * 2003-03-26 2008-04-30 Wyeth Corp Immunogenic composition and methods
AU2004223808B2 (en) * 2003-03-27 2009-03-26 Ottawa Health Research Institute Mutant vesicular stomatitis viruses and use thereof
US20090162321A1 (en) * 2007-12-20 2009-06-25 Wyeth Methods for packaging propagation-defective vesicular stomatitis virus vectors using a stable cell line that expresses g protein

Also Published As

Publication number Publication date
BRPI1009616A2 (pt) 2019-07-16
WO2010142030A1 (en) 2010-12-16
EP2440244A1 (en) 2012-04-18
AU2010258047B2 (en) 2016-01-14
AU2010258047A1 (en) 2011-12-22
US20120100176A1 (en) 2012-04-26
JP5675789B2 (ja) 2015-02-25
EP2440244A4 (en) 2013-05-29
KR101723900B1 (ko) 2017-04-07
WO2010142030A8 (en) 2011-12-29
EP2440244B1 (en) 2015-01-28
KR20120032486A (ko) 2012-04-05
CA2764903A1 (en) 2010-12-16
ES2533345T3 (es) 2015-04-09
JP2012529427A (ja) 2012-11-22
US9248178B2 (en) 2016-02-02
CA2764903C (en) 2017-10-31
BRPI1009616B1 (pt) 2021-05-11

Similar Documents

Publication Publication Date Title
BRPI1009616A2 (pt) diferentes sorotipos de vírus da estomatite vesicular como vetores de expressão para regimes de imunização
ECSP10010413A (es) Inhibidores macrociclicos de serina proteasa
CL2013003360A1 (es) “compuestos derivados de 4-aril-n-[3-(sulfonimidoil)fenil]-1,3,5-triazin-2-amina sustituidos, inhibidores cdk; compuestos intermediarios, composición y combinación farmacéutica que los comprende; y su uso en el tratamiento de enfermedades hiperproliferativas, infecciosas inducidas por virus y/o cardiovasculares”. pct
BRPI0909123B8 (pt) anticorpos monoclonais, vetor de expressão, célula hospedeira, composição farmacêutica, uso do referido anticorpo, kit de diagnóstico e métodos de ensaio para detectar a presença de epítopos de vírus de influenza a
BRPI0916235A2 (pt) composto, composição farmacêutica, uso do composto ou da composição, e, método para tratar um paciente infectado com hcv
NO20090194L (no) Rekombinant viral vaksine
MX2013007211A (es) Circovirus porcino tipo 2 (pcv2), composicion inmunogenica que contiene el mismo, equipo de prueba y aplicacion del mismo.
BRPI0923341B8 (pt) oligonucleotideo imunoestimulador, vacina compreendendo o mesmo e seu uso
ECSP12011685A (es) Inmunoconjugados dirigidos
BR112014027128A2 (pt) antígenos associados à próstata e regimes de imunoterapia baseada em vacina
BR112016028816A2 (pt) combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório, e, kit.
BR112017016417A2 (pt) moléculas de ligação dirigidas contra hemaglutinina da gripe e seus usos
AR073452A1 (es) Proteinas de fusion que comprende dos o mas antigenos de leishmania y su uso en el diagnostico y tratamiento de leishmaniasis
BRPI0905725B8 (pt) vacina e embalagem farmacêutica
UY33196A (es) Antidotos de anticoagulantes
UY33797A (es) Composiciones farmacéuticas para el tratamiento del vhc
CL2008000611A1 (es) Procedimiento para fomentar respuesta inmunitaria frente a un patogeno que comprende administrar i) uno o mas polipeptidos inmunogenicos derivados del patogeno, ii) uno o mas vectores adenoviricos que comprenden uno o mas polinucleotidos que codifica
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
IL289420A (en) Arthrospira platensis non-parenteral therapeutic delivery platform
CL2013001141A1 (es) Compuestos derivados de heterociclos condensados, inhibidores del virus de la hepatitis c; composicion farmaceutica que los contiene; y su uso para el tratamiento de la infeccion por el virus de la hepatitis c.
EP2720716A4 (en) HEALTH BASED COMPOSITIONS AND METHOD FOR TREATING OR PREVENTING DELTA HEPATITIS VIRUS INFECTION
CL2004000270A1 (es) Compuestos derivados de pirazol, sus sales de adicion acidas,trastornos de vih y virus geneticamente relacionados. hidratos, solvatos; composiciones farmaceuticas; y su uso en el tramiento de trastornos del vih y virus geneticamente relacionados.
BR112014013078A2 (pt) aparelho dental
CL2020001358A1 (es) Cepa vacunal de brucella modificada para el tratamiento de brucelosis
BR112015030566A2 (pt) aparelho para a transferência de pessoas e / ou de mercadorias para ou a partir de um navio

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/06/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/06/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2830 DE 01-04-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.